Florence Joly

Research interests

Publications

• ESGO/ESTRO/ESP Guidelines for the management of patients with cervical cancer – Update 2023*

  International Journal of Gynecological Cancer · 2023 · https://doi.org/10.1136/ijgc-2023-004429

• Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial

  The Lancet · 2023 · 10.1016/s0140-6736(23)02405-4

• ESMO Expert Consensus Statements on Cancer Survivorship: promoting high-quality survivorship care and research in Europe

  Annals of Oncology · 2022 · https://doi.org/10.1016/j.annonc.2022.07.1941

• Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

  Annals of Oncology · 2022 · 10.1016/j.annonc.2022.05.009

• Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study

  The Lancet Oncology · 2022 · https://doi.org/10.1016/s1470-2045(21)00660-4

• Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial

  The Lancet Oncology · 2021 · https://doi.org/10.1016/s1470-2045(21)00152-2

• Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial

  The Lancet Oncology · 2021 · https://doi.org/10.1016/s1470-2045(21)00073-5

• Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial

  The Lancet Oncology · 2020 · 10.1016/s1470-2045(20)30541-6

• Cancer-related cognitive impairment: an update on state of the art, detection, and management strategies in cancer survivors

  Annals of Oncology · 2019 · 10.1093/annonc/mdz410

• ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease

  Annals of Oncology · 2019 · 10.1093/annonc/mdz062

• Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies

  European Urology · 2018 · 10.1016/j.eururo.2018.02.001

• ESMO Consensus Conference on testicular germ cell cancer: diagnosis, treatment and follow-up

  Annals of Oncology · 2018 · https://doi.org/10.1093/annonc/mdy217

• BRAF Inhibition in BRAF V600 -Mutant Gliomas: Results From the VE-BASKET Study

  Journal of Clinical Oncology · 2018 · https://doi.org/10.1200/jco.2018.78.9990

• Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial

  The Lancet Oncology · 2017 · https://doi.org/10.1016/s1470-2045(17)30469-2

• Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial

  The Lancet · 2017 · https://doi.org/10.1016/s0140-6736(17)32365-6

• Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial

  The Lancet · 2017 · https://doi.org/10.1016/s0140-6736(17)32440-6

• Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: recurrent disease

  Annals of Oncology · 2016 · 10.1093/annonc/mdw663

• Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial

  European Urology · 2015 · 10.1016/j.eururo.2015.11.005

• Impact of Cancer and Its Treatments on Cognitive Function: Advances in Research From the Paris International Cognition and Cancer Task Force Symposium and Update Since 2012

  Journal of Pain and Symptom Management · 2015 · 10.1016/j.jpainsymman.2015.06.019

• Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial

  The Lancet Oncology · 2015 · https://doi.org/10.1016/s1470-2045(15)00086-8

• Patient-Reported Outcome Results From the Open-Label Phase III AURELIA Trial Evaluating Bevacizumab-Containing Therapy for Platinum-Resistant Ovarian Cancer

  Journal of Clinical Oncology · 2014 · 10.1200/jco.2013.51.4240

• Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3–pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial

  The Lancet Oncology · 2014 · 10.1016/s1470-2045(14)71160-x

• A Phase I/II, Multiple-Dose, Dose-Escalation Study of Siltuximab, an Anti-Interleukin-6 Monoclonal Antibody, in Patients with Advanced Solid Tumors

  Clinical Cancer Research · 2014 · 10.1158/1078-0432.ccr-13-2200

• Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial

  The Lancet Oncology · 2013 · 10.1016/s1470-2045(12)70560-0

• Expansion of Autoreactive Unresponsive CD21−/low B Cells in Sjögren's Syndrome–Associated Lymphoproliferation

  Arthritis & Rheumatism · 2012 · 10.1002/art.37828

• Regulatory T-Cell Responses to Low-Dose Interleukin-2 in HCV-Induced Vasculitis

  New England Journal of Medicine · 2011 · https://doi.org/10.1056/nejmoa1105143

• Pegylated Liposomal Doxorubicin and Carboplatin Compared With Paclitaxel and Carboplatin for Patients With Platinum-Sensitive Ovarian Cancer in Late Relapse

  Journal of Clinical Oncology · 2010 · 10.1200/jco.2009.25.7519

• An international prospective study of the EORTC cancer in-patient satisfaction with care measure (EORTC IN-PATSAT32)

  European Journal of Cancer · 2005 · https://doi.org/10.1016/j.ejca.2005.04.041

Current projects

No projects listed.